ALNYLAM PHARMACEUTICALS, INC. Payments to Acquire Debt Securities, Available-for-sale
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Payments to Acquire Debt Securities, Available-for-sale of $837.30 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-07-30
- ALNYLAM PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $235.91M, a 51.53% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $207.97M, a 51.68% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-06-30 was $459.56M, a 54.36% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-03-31 was $401.64M, a 4.40% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for fiscal 2025 was $1.31B, a 20.17% decline from fiscal 2024.
- ALNYLAM PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for fiscal 2024 was $1.63B, a 10.34% decline from fiscal 2023.
- ALNYLAM PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for fiscal 2023 was $1.82B, a 7.76% decline from fiscal 2022.
- ALNYLAM PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for fiscal 2022 was $1.98B, a 19.37% increase from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $837.30M 10-Q · filed 2026-07-30 | |||
| 2025-12-31 | $235.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $443.88M derived: sum of 2 quarters · filed 2026-02-12 | $903.44M derived: sum of 3 quarters · filed 2026-07-30 | $1.31B 10-K · filed 2026-02-12 |
| 2025-09-30 | $207.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $667.53M derived: sum of 2 quarters · filed 2026-07-30 | $1.07B 10-Q · filed 2025-10-30 | $1.56B derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $459.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $861.20M 10-Q · filed 2026-07-30 | $1.35B derived: sum of 3 quarters · filed 2026-07-30 | $1.78B derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $401.64M 10-Q · filed 2025-05-01 | $888.35M derived: sum of 2 quarters · filed 2026-02-12 | $1.32B derived: sum of 3 quarters · filed 2026-02-12 | $1.62B derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-12-31 | $486.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $917.09M derived: sum of 2 quarters · filed 2026-02-12 | $1.21B derived: sum of 3 quarters · filed 2026-02-12 | $1.63B 10-K · filed 2026-02-12 |
| 2024-09-30 | $430.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $728.09M derived: sum of 2 quarters · filed 2025-10-30 | $1.15B 10-Q · filed 2025-10-30 | $1.74B derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-06-30 | $297.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $717.83M 10-Q · filed 2025-07-31 | $1.31B derived: sum of 3 quarters · filed 2026-02-12 | $1.73B derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-03-31 | $420.12M 10-Q · filed 2025-05-01 | $1.01B derived: sum of 2 quarters · filed 2026-02-12 | $1.43B derived: sum of 3 quarters · filed 2026-02-12 | $1.81B derived: sum of 4 quarters · filed 2026-02-12 |
| 2023-12-31 | $589.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $1.01B derived: sum of 2 quarters · filed 2026-02-12 | $1.39B derived: sum of 3 quarters · filed 2026-02-12 | $1.82B 10-K · filed 2026-02-12 |
| 2023-09-30 | $421.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $798.60M derived: sum of 2 quarters · filed 2024-10-31 | $1.23B 10-Q · filed 2024-10-31 | $1.96B derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-06-30 | $377.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $812.89M 10-Q · filed 2024-08-01 | $1.54B derived: sum of 3 quarters · filed 2025-02-13 | $1.69B derived: sum of 4 quarters · filed 2025-02-13 |
| 2023-03-31 | $435.75M 10-Q · filed 2024-05-02 | $1.16B derived: sum of 2 quarters · filed 2025-02-13 | $1.32B derived: sum of 3 quarters · filed 2025-02-13 | $1.78B derived: sum of 4 quarters · filed 2025-02-13 |
| 2022-12-31 | $723.38M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $880.69M derived: sum of 2 quarters · filed 2025-02-13 | $1.34B derived: sum of 3 quarters · filed 2025-02-13 | $1.98B 10-K · filed 2025-02-13 |
| 2022-09-30 | $157.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $618.88M derived: sum of 2 quarters · filed 2023-11-02 | $1.25B 10-Q · filed 2023-11-02 | $1.94B derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $461.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $1.10B 10-Q · filed 2023-08-03 | $1.78B derived: sum of 3 quarters · filed 2024-02-15 | $2.24B derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $634.71M 10-Q · filed 2023-05-04 | $1.32B derived: sum of 2 quarters · filed 2024-02-15 | $1.78B derived: sum of 3 quarters · filed 2024-02-15 | $1.94B derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | $682.97M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $1.14B derived: sum of 2 quarters · filed 2024-02-15 | $1.31B derived: sum of 3 quarters · filed 2024-02-15 | $1.66B 10-K · filed 2024-02-15 |
| 2021-09-30 | $458.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | $627.19M derived: sum of 2 quarters · filed 2022-10-27 | $973.15M 10-Q · filed 2022-10-27 | $1.53B derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $168.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-28 | $514.82M 10-Q · filed 2022-07-28 | $1.07B derived: sum of 3 quarters · filed 2023-02-23 | $1.40B derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $345.95M 10-Q · filed 2022-04-28 | $902.13M derived: sum of 2 quarters · filed 2023-02-23 | $1.23B derived: sum of 3 quarters · filed 2023-02-23 | $1.98B derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $556.17M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $885.21M derived: sum of 2 quarters · filed 2023-02-23 | $1.63B derived: sum of 3 quarters · filed 2023-02-23 | $2.03B 10-K · filed 2023-02-23 |
| 2020-09-30 | $329.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | $1.07B derived: sum of 2 quarters · filed 2021-10-28 | $1.47B 10-Q · filed 2021-10-28 | $2.10B derived: sum of 4 quarters · filed 2022-02-10 |
| 2020-06-30 | $744.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $1.14B 10-Q · filed 2021-08-03 | $1.77B derived: sum of 3 quarters · filed 2022-02-10 | $2.38B derived: sum of 4 quarters · filed 2022-02-10 |
| 2020-03-31 | $396.41M 10-Q · filed 2021-04-29 | $1.03B derived: sum of 2 quarters · filed 2022-02-10 | $1.64B derived: sum of 3 quarters · filed 2022-02-10 | $2.22B derived: sum of 4 quarters · filed 2022-02-10 |
| 2019-12-31 | $630.29M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-10 | $1.24B derived: sum of 2 quarters · filed 2022-02-10 | $1.82B derived: sum of 3 quarters · filed 2022-02-10 | $2.08B 10-K · filed 2022-02-10 |
| 2019-09-30 | $611.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $1.19B derived: sum of 2 quarters · filed 2020-11-05 | $1.45B 10-Q · filed 2020-11-05 | $1.56B derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-06-30 | $577.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $834.56M 10-Q · filed 2020-08-06 | $946.22M derived: sum of 3 quarters · filed 2021-02-11 | $1.30B derived: sum of 4 quarters · filed 2021-02-11 |
| 2019-03-31 | $257.00M 10-Q · filed 2020-05-06 | $368.66M derived: sum of 2 quarters · filed 2021-02-11 | $718.25M derived: sum of 3 quarters · filed 2021-02-11 | $1.00B derived: sum of 4 quarters · filed 2021-02-11 |
| 2018-12-31 | $111.66M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $461.26M derived: sum of 2 quarters · filed 2021-02-11 | $745.61M derived: sum of 3 quarters · filed 2021-02-11 | $1.10B 10-K · filed 2021-02-11 |
| 2018-09-30 | $349.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $633.95M derived: sum of 2 quarters · filed 2019-10-31 | $992.38M 10-Q · filed 2019-10-31 | $1.38B derived: sum of 4 quarters · filed 2020-02-13 |
| 2018-06-30 | $284.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $642.79M 10-Q · filed 2019-08-06 | $1.03B derived: sum of 3 quarters · filed 2020-02-13 | $1.31B derived: sum of 4 quarters · filed 2020-02-13 |
| 2018-03-31 | $358.43M 10-Q · filed 2019-05-02 | $749.86M derived: sum of 2 quarters · filed 2020-02-13 | $1.02B derived: sum of 3 quarters · filed 2020-02-13 | $1.18B derived: sum of 4 quarters · filed 2020-02-13 |
| 2017-12-31 | $391.43M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | $666.27M derived: sum of 2 quarters · filed 2020-02-13 | $816.65M derived: sum of 3 quarters · filed 2020-02-13 | $903.46M 10-K · filed 2020-02-13 |
| 2017-09-30 | $274.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $425.22M derived: sum of 2 quarters · filed 2018-11-07 | $512.03M 10-Q · filed 2018-11-07 | $655.67M derived: sum of 4 quarters · filed 2019-02-14 |
| 2017-06-30 | $150.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $237.18M 10-Q · filed 2018-08-02 | $380.83M derived: sum of 3 quarters · filed 2019-02-14 | $638.50M derived: sum of 4 quarters · filed 2019-02-14 |
| 2017-03-31 | $86.80M 10-Q · filed 2018-05-04 | $230.45M derived: sum of 2 quarters · filed 2019-02-14 | $488.12M derived: sum of 3 quarters · filed 2019-02-14 | $681.55M derived: sum of 4 quarters · filed 2019-02-14 |
| 2016-12-31 | $143.65M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-14 | $401.32M derived: sum of 2 quarters · filed 2019-02-14 | $594.75M derived: sum of 3 quarters · filed 2019-02-14 | $759.31M 10-K · filed 2019-02-14 |
| 2016-09-30 | $257.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $451.10M derived: sum of 2 quarters · filed 2017-11-07 | $615.66M 10-Q · filed 2017-11-07 | $751.47M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-06-30 | $193.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $357.99M 10-Q · filed 2017-08-09 | $493.79M derived: sum of 3 quarters · filed 2018-02-15 | $574.16M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-03-31 | $164.56M 10-Q · filed 2017-05-05 | $300.36M derived: sum of 2 quarters · filed 2018-02-15 | $380.73M derived: sum of 3 quarters · filed 2018-02-15 | $690.79M derived: sum of 4 quarters · filed 2018-02-15 |
| 2015-12-31 | $135.80M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $216.17M derived: sum of 2 quarters · filed 2018-02-15 | $526.23M derived: sum of 3 quarters · filed 2018-02-15 | $1.03B 10-K · filed 2018-02-15 |
| 2015-09-30 | $80.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $390.42M derived: sum of 2 quarters · filed 2016-11-03 | $898.04M 10-Q · filed 2016-11-03 | $1.02B derived: sum of 4 quarters · filed 2017-02-15 |
| 2015-06-30 | $310.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $817.67M 10-Q · filed 2016-08-04 | $942.77M derived: sum of 3 quarters · filed 2017-02-15 | $1.03B derived: sum of 4 quarters · filed 2017-02-15 |
| 2015-03-31 | $507.62M 10-Q · filed 2016-05-04 | $632.72M derived: sum of 2 quarters · filed 2017-02-15 | $716.88M derived: sum of 3 quarters · filed 2017-02-15 | $997.79M derived: sum of 4 quarters · filed 2017-02-15 |
| 2014-12-31 | $125.10M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-15 | $209.26M derived: sum of 2 quarters · filed 2017-02-15 | $490.18M derived: sum of 3 quarters · filed 2017-02-15 | $977.77M 10-K · filed 2017-02-15 |
| 2014-09-30 | $84.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $365.07M derived: sum of 2 quarters · filed 2015-11-09 | $852.67M 10-Q · filed 2015-11-09 | $881.78M derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-06-30 | $280.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | $768.51M 10-Q · filed 2015-08-07 | $797.62M derived: sum of 3 quarters · filed 2016-02-12 | $858.39M derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-03-31 | $487.60M 10-Q · filed 2015-05-08 | $516.71M derived: sum of 2 quarters · filed 2016-02-12 | $577.48M derived: sum of 3 quarters · filed 2016-02-12 | $664.83M derived: sum of 4 quarters · filed 2016-02-12 |
| 2013-12-31 | $29.11M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12 | $89.88M derived: sum of 2 quarters · filed 2016-02-12 | $177.23M derived: sum of 3 quarters · filed 2016-02-12 | $364.31M 10-K · filed 2016-02-12 |
| 2013-09-30 | $60.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $148.12M derived: sum of 2 quarters · filed 2014-11-06 | $335.20M 10-Q · filed 2014-11-06 | |
| 2013-06-30 | $87.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-08 | $274.43M 10-Q · filed 2014-08-08 | ||
| 2013-03-31 | $187.08M 10-Q · filed 2014-05-09 | |||
| 2012-12-31 | $277.13M 10-K · filed 2015-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |